Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (12): 1203-1208.DOI: 10.3969/j.issn.1673-8640.2025.12.011
CHEN Kun, XU Guowei, WANG Qiuli
Received:2024-04-12
Revised:2025-01-20
Online:2025-12-30
Published:2025-12-26
CLC Number:
CHEN Kun, XU Guowei, WANG Qiuli. Expression changes of plasma lncRNA PINK1-AS and miR-532-5p in patients with ischemic stroke and their effects on sleep quality and cognitive function[J]. Laboratory Medicine, 2025, 40(12): 1203-1208.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.12.011
| 基因名称 | 上游引物(5'~3') | 下游引物(5'~3') |
|---|---|---|
| lncRNA PINK1-AS | CACTCGGACGCGACAGTC | ACGCCTATAGGACTGG |
| GAPDH | CCTGACGCGTCAGCGAGTC | GACAGACTGCTAGAGGG |
| miR-532-5p | CCTGAC GACGCAAGTC | GAGACTGACTGAGGG |
| U6 | CCAGACT ATCGACGAGTC | GACGTGAAGGGCGCTACTG |
| 基因名称 | 上游引物(5'~3') | 下游引物(5'~3') |
|---|---|---|
| lncRNA PINK1-AS | CACTCGGACGCGACAGTC | ACGCCTATAGGACTGG |
| GAPDH | CCTGACGCGTCAGCGAGTC | GACAGACTGCTAGAGGG |
| miR-532-5p | CCTGAC GACGCAAGTC | GAGACTGACTGAGGG |
| U6 | CCAGACT ATCGACGAGTC | GACGTGAAGGGCGCTACTG |
| 组别 | 例数 | lncRNA PINK1-AS | miR-532-5p |
|---|---|---|---|
| 正常对照组 | 124 | 1.02±0.24 | 1.01±0.23 |
| AIS组 | 129 | 1.52±0.40 | 0.67±0.16 |
| t值 | 11.997 | 13.693 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | lncRNA PINK1-AS | miR-532-5p |
|---|---|---|---|
| 正常对照组 | 124 | 1.02±0.24 | 1.01±0.23 |
| AIS组 | 129 | 1.52±0.40 | 0.67±0.16 |
| t值 | 11.997 | 13.693 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | 性别 | 年龄/岁 | BMI/(kg·m-2) | 吸烟史/ [例(%)] | 饮酒史/ [例(%)] | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 男/[例(%)] | 女/[例(%)] | |||||||||
| 睡眠质量好组 | 68 | 41(60.29) | 27(39.71) | 65.94±9.24 | 22.98±2.76 | 38(55.88) | 10(14.71) | |||
| 睡眠质量差组 | 61 | 33(54.10) | 28(45.90) | 66.03±9.12 | 23.01±2.85 | 31(50.82) | 8(13.11) | |||
| 统计值 | 0.505 | 0.056 | 0.061 | 0.331 | 0.068 | |||||
| P值 | 0.477 | 0.956 | 0.952 | 0.565 | 0.795 | |||||
| 组别 | 高血压史/[例(%)] | 糖尿病史/[例(%)] | 空腹血糖/(mmol·L-1) | 发病至入院时间/h | ||||||
| 睡眠质量好组 | 35(51.47) | 11(16.18) | 5.98±1.62 | 3.12±1.10 | ||||||
| 睡眠质量差组 | 32(52.46) | 7(11.48) | 6.14±1.58 | 3.20±1.15 | ||||||
| 统计值 | 0.013 | 0.592 | 0.567 | 0.404 | ||||||
| P值 | 0.911 | 0.442 | 0.572 | 0.687 | ||||||
| 组别 | 受教育年限/年 | 脑梗死分型 | lncRNA PINK1-AS | miR-532-5p | ||||||
| 前循环/[例(%)] | 后循环/[例(%)] | |||||||||
| 睡眠质量好组 | 9.49±1.40 | 38(55.88) | 30(44.12) | 1.35±0.32 | 0.81±0.18 | |||||
| 睡眠质量差组 | 9.75±1.56 | 32(52.46) | 29(47.54) | 1.71±0.45 | 0.51±0.14 | |||||
| 统计值 | 0.998 | 0.152 | 5.276 | 10.479 | ||||||
| P值 | 0.320 | 0.697 | <0.001 | <0.001 | ||||||
| 组别 | 例数 | 性别 | 年龄/岁 | BMI/(kg·m-2) | 吸烟史/ [例(%)] | 饮酒史/ [例(%)] | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 男/[例(%)] | 女/[例(%)] | |||||||||
| 睡眠质量好组 | 68 | 41(60.29) | 27(39.71) | 65.94±9.24 | 22.98±2.76 | 38(55.88) | 10(14.71) | |||
| 睡眠质量差组 | 61 | 33(54.10) | 28(45.90) | 66.03±9.12 | 23.01±2.85 | 31(50.82) | 8(13.11) | |||
| 统计值 | 0.505 | 0.056 | 0.061 | 0.331 | 0.068 | |||||
| P值 | 0.477 | 0.956 | 0.952 | 0.565 | 0.795 | |||||
| 组别 | 高血压史/[例(%)] | 糖尿病史/[例(%)] | 空腹血糖/(mmol·L-1) | 发病至入院时间/h | ||||||
| 睡眠质量好组 | 35(51.47) | 11(16.18) | 5.98±1.62 | 3.12±1.10 | ||||||
| 睡眠质量差组 | 32(52.46) | 7(11.48) | 6.14±1.58 | 3.20±1.15 | ||||||
| 统计值 | 0.013 | 0.592 | 0.567 | 0.404 | ||||||
| P值 | 0.911 | 0.442 | 0.572 | 0.687 | ||||||
| 组别 | 受教育年限/年 | 脑梗死分型 | lncRNA PINK1-AS | miR-532-5p | ||||||
| 前循环/[例(%)] | 后循环/[例(%)] | |||||||||
| 睡眠质量好组 | 9.49±1.40 | 38(55.88) | 30(44.12) | 1.35±0.32 | 0.81±0.18 | |||||
| 睡眠质量差组 | 9.75±1.56 | 32(52.46) | 29(47.54) | 1.71±0.45 | 0.51±0.14 | |||||
| 统计值 | 0.998 | 0.152 | 5.276 | 10.479 | ||||||
| P值 | 0.320 | 0.697 | <0.001 | <0.001 | ||||||
| 组别 | 例数 | 性别 | 年龄/岁 | BMI/(kg·m-2) | 吸烟史/ [例(%)] | 饮酒史/ [例(%)] | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 男/[例(%)] | 女/[例(%)] | |||||||||
| 认知正常组 | 89 | 49(55.06) | 40(44.94) | 65.90±9.04 | 23.02±2.97 | 47(52.81) | 12(13.48) | |||
| 认知障碍组 | 40 | 25(62.50) | 15(37.50) | 66.10±9.45 | 22.97±3.07 | 22(55.00) | 6(15.00) | |||
| 统计值 | 0.625 | 0.115 | 0.088 | 0.053 | 0.053 | |||||
| P值 | 0.429 | 0.909 | 0.930 | 0.817 | 0.818 | |||||
| 组别 | 高血压史/[例(%)] | 糖尿病史/[例(%)] | 空腹血糖/(mmol·L-1) | 发病至入院时间/h | ||||||
| 认知正常组 | 44(49.44) | 11(12.36) | 6.04±1.70 | 3.13±0.92 | ||||||
| 认知障碍组 | 23(57.50) | 7(17.50) | 6.10±1.65 | 3.20±1.18 | ||||||
| 统计值 | 0.719 | 0.607 | 0.187 | 0.365 | ||||||
| P值 | 0.397 | 0.436 | 0.852 | 0.716 | ||||||
| 组别 | 受教育年限/年 | 脑梗死分型 | lncRNA PINK1-AS | miR-532-5p | ||||||
| 前循环/[例(%)] | 后循环/[例(%)] | |||||||||
| 认知正常组 | 9.54±1.48 | 48(53.93) | 41(46.07) | 1.33±0.28 | 0.77±0.17 | |||||
| 认知障碍组 | 9.70±1.62 | 22(55.00) | 18(45.00) | 1.94±0.48 | 0.45±0.15 | |||||
| 统计值 | 0.551 | 0.013 | 9.061 | 10.243 | ||||||
| P值 | 0.582 | 0.910 | <0.001 | <0.001 | ||||||
| 组别 | 例数 | 性别 | 年龄/岁 | BMI/(kg·m-2) | 吸烟史/ [例(%)] | 饮酒史/ [例(%)] | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 男/[例(%)] | 女/[例(%)] | |||||||||
| 认知正常组 | 89 | 49(55.06) | 40(44.94) | 65.90±9.04 | 23.02±2.97 | 47(52.81) | 12(13.48) | |||
| 认知障碍组 | 40 | 25(62.50) | 15(37.50) | 66.10±9.45 | 22.97±3.07 | 22(55.00) | 6(15.00) | |||
| 统计值 | 0.625 | 0.115 | 0.088 | 0.053 | 0.053 | |||||
| P值 | 0.429 | 0.909 | 0.930 | 0.817 | 0.818 | |||||
| 组别 | 高血压史/[例(%)] | 糖尿病史/[例(%)] | 空腹血糖/(mmol·L-1) | 发病至入院时间/h | ||||||
| 认知正常组 | 44(49.44) | 11(12.36) | 6.04±1.70 | 3.13±0.92 | ||||||
| 认知障碍组 | 23(57.50) | 7(17.50) | 6.10±1.65 | 3.20±1.18 | ||||||
| 统计值 | 0.719 | 0.607 | 0.187 | 0.365 | ||||||
| P值 | 0.397 | 0.436 | 0.852 | 0.716 | ||||||
| 组别 | 受教育年限/年 | 脑梗死分型 | lncRNA PINK1-AS | miR-532-5p | ||||||
| 前循环/[例(%)] | 后循环/[例(%)] | |||||||||
| 认知正常组 | 9.54±1.48 | 48(53.93) | 41(46.07) | 1.33±0.28 | 0.77±0.17 | |||||
| 认知障碍组 | 9.70±1.62 | 22(55.00) | 18(45.00) | 1.94±0.48 | 0.45±0.15 | |||||
| 统计值 | 0.551 | 0.013 | 9.061 | 10.243 | ||||||
| P值 | 0.582 | 0.910 | <0.001 | <0.001 | ||||||
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| lncRNA PINK1-AS | 0.809(0.733~0.885) | 1.59 | 62.39 | 88.15 | 0.505 |
| miR-532-5p | 0.857(0.810~0.923) | 0.67 | 88.54 | 73.48 | 0.620 |
| 联合检测 | 0.928(0.880~0.977) | 0.94 | 95.19 | 80.94 | 0.761 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| lncRNA PINK1-AS | 0.809(0.733~0.885) | 1.59 | 62.39 | 88.15 | 0.505 |
| miR-532-5p | 0.857(0.810~0.923) | 0.67 | 88.54 | 73.48 | 0.620 |
| 联合检测 | 0.928(0.880~0.977) | 0.94 | 95.19 | 80.94 | 0.761 |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| lncRNA PINK1-AS | 0.842(0.758~0.825) | 1.72 | 72.58 | 86.49 | 0.591 |
| miR-532-5p | 0.864(0.796~0.932) | 0.61 | 90.03 | 70.72 | 0.608 |
| 联合检测 | 0.940(0.887~0.994) | 0.92 | 87.56 | 97.73 | 0.853 |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| lncRNA PINK1-AS | 0.842(0.758~0.825) | 1.72 | 72.58 | 86.49 | 0.591 |
| miR-532-5p | 0.864(0.796~0.932) | 0.61 | 90.03 | 70.72 | 0.608 |
| 联合检测 | 0.940(0.887~0.994) | 0.92 | 87.56 | 97.73 | 0.853 |
| [1] |
GAO W J, BAO W J, SUN S J. An evidence-based nursing intervention decreases anxiety,depression,sleep quality and somatic symptoms of patients with acute ischemic stroke[J]. Neuropsychiatr Dis Treat, 2022,18:2443-2451.
DOI URL |
| [2] |
HASAN F, GORDON C, WU D, et al. Dynamic prevalence of sleep disorders following stroke or transient ischemic attack:systematic review and meta-analysis[J]. Stroke, 2021, 52(2):655-663.
DOI URL |
| [3] | 刘玉双, 熊思艺. 缺血性卒中后睡眠质量对老年人认知功能的影响[J]. 哈尔滨医药, 2022, 42(1):5-7. |
| [4] |
LV Y, WANG Y, SONG Y, et al. LncRNA PINK1-AS promotes Gαi1-driven gastric cancer tumorigenesis by sponging microRNA-200a[J]. Oncogene, 2021, 40(22):3826-3844.
DOI PMID |
| [5] |
LUO K, XU S, ZHAO J, et al. Upregulation of lncRNA PINK1-AS predicts the distant metastasis of patients with small cell lung cancer[J]. Mol Biotechnol, 2023, 65(1):28-33.
DOI |
| [6] | YANG Z B, XIANG Y, ZUO M L, et al. LncRNA PINK1-AS aggravates cerebral ischemia/reperfusion oxidative stress injury through regulating ATF2 by sponging miR-203[J]. Oxid Med Cell Longev, 2022,2022:1296816. |
| [7] |
MU J, CHENG X, ZHONG S, et al. Neuroprotective effects of miR-532-5p against ischemic stroke[J]. Metab Brain Dis, 2020, 35(5):753-763.
DOI PMID |
| [8] | 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682. |
| [9] | NIU S, WU Q, DING S, et al. Comparison of three measures for insomnia in ischemic stroke patients:Pittsburgh sleep quality index,insomnia severity index,and Athens insomnia scale[J]. Front Neurol, 2023,14:1118322. |
| [10] | LIU Z, YANG W, CHEN J, et al. Circulating HMGB1 in acute ischemic stroke and its association with post-stroke cognitive impairment[J]. PeerJ, 2024,12:e17309. |
| [11] |
畅慧君, 张敏, 张其相. 血清Hcy水平与接受静脉溶栓治疗急性脑梗死患者短期预后的相关性[J]. 检验医学, 2023, 38(11):1057-1061.
DOI |
| [12] | ZHANG Z, WANG M, GILL D, et al. Genetically predicted sleep traits and functional outcome after ischemic stroke:a mendelian randomization study[J]. Neurology, 2023, 100(11):e1159-e1165. |
| [13] | EL HUSSEINI N, KATZAN I L, ROST N S, et al. Cognitive impairment after ischemic and hemorrhagic stroke:a scientific statement from the American Heart Association/American Stroke Association[J]. Stroke, 2023, 54(6):e272-e291. |
| [14] |
VASUDEVA K, DUTTA A, MUNSHI A. Role of lncRNAs in the development of ischemic stroke and their therapeutic potential[J]. Mol Neurobiol, 2021, 58(8):3712-3728.
DOI PMID |
| [15] | PATOUGHI M, GHAFOURI-FARD S, ARSANG-JANG S, et al. Expression analysis of PINK1 and PINK1-AS in multiple sclerosis patients versus healthy subjects[J]. Nucleosides Nucleotides Nucleic Acids, 2021, 40(2):157-165. |
| [16] |
CIACCIO A M, TUTTOLOMONDO A. Exosomal miRNAs as biomarkers of ischemic stroke[J]. Brain Sci, 2023, 13(12):1647.
DOI URL |
| [17] | BRITO L M, RIBEIRO-DOS-SANTOS Â, VIDAL A F, et al. Differential expression and miRNA-gene interactions in early and late mild cognitive impairment[J]. Biology(Basel), 2020, 9(9):251. |
| [18] |
顾梅, 裴小锐, 常京豪. 血浆外泌体 miR-92a-5p 和 miR-532-5p在老年血管性认知障碍患者中的表达意义[J]. 立体定向和功能性神经外科杂志, 2022, 35(6):359-364.
DOI |
| [19] |
NIU S, LIU X, WU Q, et al. Sleep quality and cognitive function after stroke:the mediating roles of depression and anxiety symptoms[J]. Int J Environ Res Public Health, 2023, 20(3):2410.
DOI URL |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||